Match Document Document Title
6419919 Method for the augmentation of gene expression  
The present invention provides a method of increasing adenoviral gene expression in a tissue of an animal, comprising the step of administering to said animal a pharmacologically effective dose of...
6413930 Use of cck-b receptor antagonists for the treatment of sleep disorders  
The use of CCK-B antagonists for the treatment of sleep disorders.
6403078 Method and compositions for treating preterm labor and premature rupture of fetal membranes  
Methods and compositions for the prevention and treatment of preterm labor and premature rupture of fetal membranes are provided. The methods of the invention inhibit the upregulated production of...
6399301 Human phospholipase A2 protein  
The invention provides a human phospholipase A2 protein PHPLA2 and polynucleotides which identify and encode PHPLA2. The invention also provides expression vectors, host cells, agonists,...
6395254 Conjugate comprising an active agent, a polypeptide and a polyether  
The present invention relates to conjugates, comprising an active substance, a polypeptide and a polyether, a process for the production of such conjugates as well as their use.
6380155 Use of vasopressin receptor antagonist for regulation of ACTH release  
A method for normalising abnormally elevated ACTH release in mammals, such as humans, which method comprises the administration of an effective, non-toxic amount of a compound which regulates the...
6376460 Method of modulating cellular activity  
The present invention is directed to compositions and methods for modulating cellular activity. The invention is particularly suited for delivering an agent which modulates cellular activity to a...
6355270 Particles for oral delivery of peptides and proteins  
Microfabricated, asymmetrical, reservoir-containing particles for use in the oral delivery of biopolymer therapeutic agents such as peptides, proteins and oligonucleotides are disclosed. The...
6355619 Peptide tumor cell growth inhibitors  
Disclosed are peptide-based compositions and methods for inhibiting and modulating the actions of CXC intercrine molecules. The antileukinate peptides described inhibit IL-8, GRO and MIP2β binding...
6348447 Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein  
The invention relates to the new use of gastrointestinal peptide hormones selected from the class consisting of glucagon-like peptide-1 (GLP-1) and derivatives thereof having anti-secretory...
6346515 Collegan-based matrix  
A collagen matrix comprises collagen fibrils which are cross-linked to one another by reducing sugar or a reducing sugar derivative. The collagen matrix may be formed into a membrane useful in...
6337315 Anti-inflammatory compositions comprising peptide derivatives of α-MSH/algal extracts  
Anti-inflammatory compositions, well suited for a wide variety of therapeutic/cosmetic applications, comprise combinatory immixture of (1) an effective anti-inflammatory amount of at least one...
6319505 Method for treating dystonia with botulinum toxin types C to G  
A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount...
6313097 Antagonists of calcitonin gene-related peptide  
Compounds of the formula (I) ##STR1##wherein A, R, R1, R2, X1, X2, X3, and Y are as defined herein, and the tautomers and the pharmaceutically acceptable salts thereof, including pharmaceutical...
6309633 Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same  
The invention provides a drug-oligomer conjugate having the following general formula: ##STR1##wherein D is a therapeutic drug moiety; H and H' are each a hydrophilic moiety, independently...
6303340 Method for producing a peptide with a pI above 8 or below 5  
A method is described for producing a peptide having a pI above 8 or below 5 wherein the peptide is expressed as a fusion protein in which it is linked to a fusion partner through an acid cleavage...
6291175 Methods for treating a neurological disease by determining BCHE genotype  
Disclosed herein is a method for treating a patient with a neurological disease by determining a patient's BCHE allele status.
6287817 Fusion proteins for protein delivery  
A protein conjugate consisting of antibody directed at the pIgR and A1 AT can be transported specifically from the basolateral surface of epithelial cells to the apical surface. This approach...
6274135 Method of using IL-11 for inflammation associated with acute pancreatitis  
Provided by the present invention are methods of treating a variety of disorders including AIDS, arthritis (rheumatoid arthritis, osteoarthritis, spondyloarthropathies), antibiotic induced...
6271202 Reduction of impairment of respiratory tract mucosal immunity  
The present invention describes methods for reducing the impairment respiratory tract mucosal immunity associated with a lack of enteral feeding or a lack of immunological stimulation of the...
6265381 Orally-active elastase inhibitors  
This invention relates to novel morpholinourea and related derivatives of pentafluoroethyl peptides which are orally active elastase inhibitors. These compounds are useful in the treatment of...
6261582 Surgical method and composition therefor  
Administration of a morphine-based analgesic paste directly to the epidural space during lumbar decompressive surgery significantly improves post-operative pain control, reduces prescribed...
6242415 Mediation of cytokines by melanin  
Methods and compositions are provided that teach the use of purified melanin compositions to treat, prevent, or ameliorate diseases that are associated with excess cytokine production. In...
6232293 Method and material for inhibiting complement  
The invention provides a method of inhibiting complement in a mammal comprising administering to the mammal an effective amount of a carrier having coupled thereto a plurality of dipeptides...
6218136 Methods of the identification of pharmaceutically active compounds  
CSBP/p38 is a MAP kinase that is activated in response to stress, endotoxin, interleukin 1 and tumor necrosis factor. Using a catalytically inactive mutant (D168A) of human CSBP2 as the bait in a...
6214343 Prevention and treatment of necrotizing enterocolitis  
Methods are described for preventing and treating necrotizing enterocolitis in animals, including humans. Antibodies directed to PAF and/or TNF are shown to have a beneficial effect in animal...
6207155 Method of eosinophil depletion with antibody to CCR 3 receptor  
Binding compositions and various methods of use of the binding compositions are provided. In particular, a method is provided which comprises administering an effective amount of the binding...
6207644 Peptide analogues containing a 7-membered lactam ring  
The invention concerns pharmaceutically useful peptide derivatives of the formula (I), P--R1 --R2 --R3 --R4, in which P, R1, R2, R3, and R4 have the various meanings defined herein, and their...
6207654 Capillary membrane stabilization and reduction of inflammation during the course of chemotherapy or antiviral treatment through the use of biodegradable macromolecules and interleukin-2  
There is provided a method of treating a human subject to prevent leakage of serum proteins from capillary endothelial junctions during a period of increased capillary permeability. The method...
6201072 Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties  
A water soluble, biodegradable ABA- or BAB-type tri-block polymer is disclosed that is made up of a major amount of a hydrophobic A polymer block made of a biodegradable polyester and a minor...
6197746 Method of using secretin for treating autism  
Secretin and secretin compositions are used for the treatment of autism and other neurological, behavioral and immunological disorders. The method includes administering an effective amount of...
6194376 Method for modulating inflammatory response comprising administering morphogen  
The invention provides methods for alleviating immune cell mediated inflammatory responses to injury to mammalian tissue. The present methods make use of osteogenic protein 1(OP-1), which is...
6190872 Method for identifying and monitoring patients at risk for systemic inflammatory conditions and apparatus for use in this method  
A method of identifying and monitoring patients at risk for developing a systemic inflammatory condition prior to development of signs and symptoms using a systemic mediator-associated physiologic...
6187744 Methods and compositions for regulating the intravascular flow and oxygenating activity of hemoglobin in a human or animal subject  
Methods for time-regulated prophylaxis or treatment of animals or humans for limited circulatory oxygen delivery induced by the inhibitory effects of a plasma-borne hemoglobin-based material on...
6180611 Peptidyl compounds  
Compounds of general formula (I): ##STR1##have utility as inhibitors of matrix metalloproteinases and TNF.
6174664 Screening method for inflammatory diseases using neutrophil defensins and lactoferrin  
The present invention provides a relatively accurate, rapid and economical method of screening a patient for the presence of inflammatory diseases such as an intraamniotic infection, bacterial...
6171590 Chemokine receptor peptide for inducing an immune response  
The present invention provides immunogenic oligopeptides derived from the chemokine receptor protein for use in compositions and methods for the treatment, and prevention of inflammatory responses.
6165459 Methods for suppressing myeloid cells with chemokines  
Described are preferred processes and compositions for suppressing myeloid cells in mammals. Preferred processes and compositions involve the use of chemokines in synergistic combinations or while...
6159711 DNA encoding rantes peptide fragments and methods of treatment with the fragments  
Modifications to RANTES can result in the modified polypeptide acting as a RANTES or MIP-1α antagonist. Such antagonists can be used in therapy to reduce inflammation. They are also useful in...
6156729 Leukemia inhibitory factor for use in modulating inflammation and pain  
A method for inhibiting and/or reducing inflammation and/or pain in an individual is provided. The method comprises administration of leukemia inhibitory factor (LIF) to a cell or an individual in...
6153592 Enhancing the bioavailability of proteolytically labile therapeutic agents  
Proteins or peptidic substances, which may be prepared from naturally occurring proteins, enhance the bioavailability of proteolytically-labile therapeutic agents which, in the absence of the...
6143331 Pharmaceutical composition which is stable during storage and contains a thymus extract  
The invention concerns a process for preparing a pharmaceutical composition of thymus factors which displays immunomodulating and anti-inflammatory properties and is stable during storage. The...
6136787 Interleukin 1β protease and interleukin 1β protease inhibitors  
There is disclosed an isolated polypeptide and derivatives thereof having protease biological activity for human precursor IL-1β and for a substrate comprising: R1 -Asp-R2 -R3wherein R1 and R3 are...
6126933 Methods of treating inflammatory bowel diseases by administering IL-11  
Provided by the present invention are topical formulations of Interleukin-11 and methods for treating a variety of disorders, including inflammatory bowel diseases (e.g., Crohn's disease,...
6117840 CS-1 peptidomimetics, compositions and methods of using the same  
The present invention contemplates a peptide that inhibits the binding between the VLA-4 receptor expressed on inflammatory leukocytes and the fibronectin CS-1 peptide expressed on endothelial...
6110896 Peptidyl compounds and their therapeutic use  
Tripeptidyl derivatives having a SH or acylS group and which are amides, have therapeutic utility via MMP or TNF inhibition.
6110891 Lectin compositions and uses thereof  
This invention provides methods for: the control of mucosal cell proliferation; the reduction and/or treatment of damage caused by a cell-damaging agent; and for the reduction and/or treatment of...
6103234 Composition comprising an antibody to macrophage-derived inflammatory mediator (MIP-2)  
An inflammatory cytokine is disclosed which has been isolated from cells that have been incubated with a stimulator material. The inflammatory cytokine comprises a protein that is capable of...
6096712 Kininogen inhibitors  
Kininogenase inhibiting peptides or peptide analogues with C-terminal related to agmatine or noragmatine.
6090777 Method to reduce myocardial injury during acute myocardial infarction  
A therapeutic or prophylactic treatment method of acute myocardial infarction, comprising administering exogenous C1-esterase inhibitor, alone or in combination with other drugs, to a patient with...